Health and Healthcare
FDA Warns Consumers to Discard Dr. Berne and LightEyez Eye Drops
Published:
The U.S. Food and Drug Administration (FDA) has issued a notice warning consumers not to purchase or use existing supplies of Dr. Berne’s MSM Eye Drops 5% Solution and LightEyez MSM Eye Drops due to “bacterial contamination, fungal contamination, or both.” (These are history’s worst medical scandals.)
[in-text-ad]
Recent testing of the eye drops showed that the products were “contaminated with microbes and were not sterile.” The FDA requires that eye drops be sterile in order to be safely used. The agency further recommends that consumers discard these products.
One of the active ingredients in both brands, methylsulfonylmethane (MSM), is an unapproved drug and is being illegally marketed in the United States. There are no legally marketed drugs containing MSM available in this country.
On Monday, the manufacturer of the drops, Dr. Berne, verbally agreed to a voluntary recall of Dr. Berne’s MSM Drops 5% Solution. The FDA also sent an email to LightEyez Ltd., maker of LightEyez MSM Eye Drops, asking to discuss the company’s product. LightEyez has not responded.
24/7 Wall St.For more information, see the FDA warning.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
